Skyviews Life Science
Skyviews Life Science is a privately held advisory and venture capital firm founded in 2018 and based in Grandvaux, Switzerland. The company specializes in personalized health by identifying investment opportunities in startups and established firms at the intersection of biotechnology, advanced nutrition, and digital health. Skyviews Life Science focuses on companies that offer innovative drugs, advanced technology platforms, preventive strategies, personalized solutions, and natural food products aimed at enhancing individual quality of life. By targeting both private and public enterprises, the firm aims to support advancements that contribute to better health outcomes.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Nutrition
one.bio
Series A in 2024
one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.
one.bio
Series A in 2022
one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.
one.bio
Venture Round in 2020
one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.